JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Editas Medicine Inc

Fermé

SecteurSoins de santé

3.05 -3.48

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.04

Max

3.19

Chiffres clés

By Trading Economics

Revenu

23M

-53M

Ventes

-1.1M

3.6M

Marge bénéficiaire

-1,487.842

Employés

246

EBITDA

23M

-49M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+22.4% upside

Dividendes

By Dow Jones

Prochains Résultats

3 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

108M

292M

Ouverture précédente

6.53

Clôture précédente

3.05

Sentiment de l'Actualité

By Acuity

50%

50%

176 / 373 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 oct. 2025, 23:28 UTC

Actions en Tendance

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 oct. 2025, 23:07 UTC

Résultats

Prudential PLC 3Q New Business Profit Up 13%

30 oct. 2025, 00:00 UTC

Résultats

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 oct. 2025, 00:00 UTC

Résultats

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 oct. 2025, 00:00 UTC

Résultats

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 oct. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 oct. 2025, 23:40 UTC

Résultats

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 oct. 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 oct. 2025, 23:25 UTC

Résultats

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 oct. 2025, 22:51 UTC

Résultats

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 oct. 2025, 22:45 UTC

Résultats

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 oct. 2025, 22:41 UTC

Résultats

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 oct. 2025, 22:41 UTC

Résultats

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 oct. 2025, 22:09 UTC

Résultats

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 oct. 2025, 22:08 UTC

Market Talk
Résultats

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 oct. 2025, 21:58 UTC

Résultats

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 oct. 2025, 21:58 UTC

Résultats

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 oct. 2025, 21:57 UTC

Résultats

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 oct. 2025, 21:54 UTC

Résultats

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 oct. 2025, 21:46 UTC

Résultats

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 oct. 2025, 21:43 UTC

Résultats

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 oct. 2025, 21:43 UTC

Résultats

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 oct. 2025, 21:42 UTC

Résultats

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 oct. 2025, 21:42 UTC

Résultats

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 oct. 2025, 21:41 UTC

Résultats

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 oct. 2025, 21:41 UTC

Résultats

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 oct. 2025, 21:41 UTC

Résultats

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 oct. 2025, 21:41 UTC

Résultats

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 oct. 2025, 21:40 UTC

Résultats

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 oct. 2025, 21:39 UTC

Résultats

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

22.4% hausse

Prévisions sur 12 Mois

Moyen 3.88 USD  22.4%

Haut 6 USD

Bas 1 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

12 ratings

5

Achat

5

Maintien

2

Vente

Score Technique

By Trading Central

1.33 / 1.54Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Neutral Evidence

Long Terme

No Evidence

Sentiment

By Acuity

176 / 373Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
help-icon Live chat